Literature DB >> 28267688

Reduction of Myocardial Ischemia-Reperfusion Injury by Inhibiting Interleukin-1 Alpha.

Adolfo G Mauro1, Eleonora Mezzaroma, Juan Torrado, Priyanka Kundur, Priyashma Joshi, Kelsey Stroud, Federico Quaini, Costanza A Lagrasta, Antonio Abbate, Stefano Toldo.   

Abstract

BACKGROUND: Interleukin-1α (IL-1α) released by dying cells is an alarmin that activates the innate immunity. We hypothesized that after myocardial ischemia-reperfusion (I/R) injury, IL-1α amplifies the myocardial damage by activating the inflammasome and caspase-1.
METHODS: Adult male CD1 mice were used. The left anterior descending coronary artery was ligated for 30 minutes, after 24 hours of reperfusion. An IL-1α blocking antibody (15 μg/kg intraperitoneally) or matching vehicle was given after reperfusion. A subgroup of mice underwent sham surgery. We assessed the effects of IL-1α blockade on caspase-1 activity, infarct size, cardiac troponin I serum levels, and left ventricular fractional shortening, 24 hours after I/R.
RESULTS: I/R led to inflammasome formation, and IL-1α blockade significantly reduced inflammasome formation, reflected by a >50% reduction in caspase-1 activity versus vehicle (P = 0.03). IL-1α blockade also reduced the infarct size (-52% infarct expressed as percentage of area at risk, and -79% for cardiac troponin I serum levels, P < 0.001 vs. vehicle) and preserved the left ventricular fractional shortening (31 ± 3% vs. 25 ± 2%, P < 0.001 vs. vehicle).
CONCLUSION: IL-1α blockade after I/R reduces the inflammasome activation, decreases the infarct size, and preserves the left ventricular function. IL-1α blockade may therefore represent a novel therapeutic strategy to reduce I/R injury.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28267688     DOI: 10.1097/FJC.0000000000000452

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

Review 1.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

Review 2.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

3.  Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.

Authors:  Benjamin W Van Tassell; Michael J Lipinski; Darryn Appleton; Charlotte S Roberts; Michael C Kontos; Nayef Abouzaki; Ryan Melchior; George Mueller; James Garnett; Justin Canada; Salvatore Carbone; Leo F Buckley; George Wohlford; Dinesh Kadariya; Cory R Trankle; Claudia Oddi Erdle; Robin Sculthorpe; Laura Puckett; Christine DeWilde; Keyur Shah; Dominick J Angiolillo; George Vetrovec; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2018-08-17       Impact factor: 2.882

Review 4.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 5.  Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.

Authors:  Stefano Toldo; Adolfo G Mauro; Zachary Cutter; Antonio Abbate
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-31       Impact factor: 4.733

6.  Investigation of the underlying hub genes and mechanisms of reperfusion injury in patients undergoing coronary artery bypass graft surgery by integrated bioinformatic analyses.

Authors:  Zhida Shen; Jiangting Lu; Jiejin Wei; Juanjuan Zhao; Meihui Wang; Ming Wang; Xiaohua Shen; Xue Lü; Binquan Zhou; Yanbo Zhao; Guosheng Fu
Journal:  Ann Transl Med       Date:  2019-11

Review 7.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

8.  Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction.

Authors:  Sumia A Bageghni; Karen E Hemmings; Nadira Y Yuldasheva; Azhar Maqbool; Filomena O Gamboa-Esteves; Neil E Humphreys; Maj Simonsen Jackson; Christopher P Denton; Sheila Francis; Karen E Porter; Justin Fx Ainscough; Emmanuel Pinteaux; Mark J Drinkhill; Neil A Turner
Journal:  JCI Insight       Date:  2019-08-08

Review 9.  Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection.

Authors:  Muntasir Billah; Anisyah Ridiandries; Usaid Allahwala; Harshini Mudaliar; Anthony Dona; Stephen Hunyor; Levon M Khachigian; Ravinay Bhindi
Journal:  Oncotarget       Date:  2019-01-04

10.  Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization.

Authors:  Nilgün Gedik; Eva Kottenberg; Matthias Thielmann; Ulrich H Frey; Heinz Jakob; Jürgen Peters; Gerd Heusch; Petra Kleinbongard
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.